Nuwiq

DRUG3 trials

Sponsors

Emory University, Octapharma

Conditions

Hemophilia ASevere Hemophilia A

Phase 4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

RecruitingNCT05935358

OctapharmaSevere Hemophilia A

Start: 2023-11-28End: 2026-09-01Target: 28Updated: 2026-05-12

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

RecruitingNCT05936580

OctapharmaHemophilia A

Start: 2026-04-01End: 2027-02-01Target: 28Updated: 2026-05-12

Unknown Phase

Treatment of Hemophilia A Patients With FVIII Inhibitors

RecruitingNCT04023019

Emory UniversityHemophilia A

Start: 2020-03-17End: 2029-06-30Target: 120Updated: 2025-09-05

Related Papers

NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study.

2025-10-28

Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).

2024-12-01

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Blood2024-11-05

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)

Therapeutic Advances in Hematology2021-01-0110 citations